Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Conference · 2026-11-18
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Okay, cool. Good afternoon, everyone. Day three of our Jeffrey's Linden Healthcare Conference. Tail end of the day. We're going to make it through. My name is Akash Shawari. I am a farm and biotech analyst here at Jefferies, and I have the pleasure of hosting the Alchemist management team and Blair. Alchemist is one of our top picks in SmidCat Biotech, largely based on kind of our growing confidence that orexin agonists are going to be backbone treatments for different types of hypersalmic syndications and potentially even more, and I'm sure we're going to talk about that today. Blair, why don't I hand it off to you for some intro questions, and we'll go.
Great. Well, thanks for having me here. It's great to see you again. You know, we're coming off a pretty transformational time for the company. This last year, we had a number of data readouts that have kind of moved us into the new space. We had the NT2 data with our Elixir Rexton program, very positive, moving us into Phase 3. We had positive results on Lume Rise for idiopathic hypersomnia, which is moving us forward on registration. And then just a few weeks ago, we announced some positive ADHD data on our Elk 7290. And we have a new training program, another orexin agonist that we've entered into the clinic. And so there's a lot been happening with the company. And as we move over into the next 12 months from now until the end of next year, we probably have about six trials or so reading out over the course of that time. We have our idiopathic hypersomnia study at the end of the year, three phase three programs, NT1, NT2, reading out in the middle of the summer. That's followed by our ADHD phase 2 dose ranging study in the early fall, and then fatigue in ELX 4510 right after that. So a lot of catalysts for the company, a lot of growth. We're pretty excited to how this portfolio is starting to shape up.
Understood. Now, you know, it's interesting. I feel like you guys try to, I remember talking to you and Richard kind of in the summer, and even going before, you try to be humble in terms of where you think erections are going. You're like, look, if Lily wants to go into this area, that's interesting, but we're really focused on this. The range of things that your team is looking at for Erexans and where you feel like there's a good capital return has really widened beyond just NT1, NT2, and IH to now MDD and ADHD, right? But I know, Blair, you're very, very focused on making sure these are prudent investments and you're really thinking about return on capital. How does ADHD and MDD, what have we seen maybe from the orexin class in NT1, NT2, IH? Helped you feel more comfortable that going into these other indications makes sense.
Yeah, it's really interesting. I think as you look at moving outside diseases of hypersomnolence, there's a lot of interesting places that you can take these molecules. And we really view this from a first principles perspective. We did a lot of work on neurotransmitter release. We did a lot of work on basic pharmacology to really understand how can you take these into new areas? Where are you going to have the most tangential outcome? What's similar to wakefulness that you could apply in a broader neuroscience indication? And things like ADHD and MDD fall right in that category. So, for example, we see in MDD, for example, that we can get a really strong synergistic effect in serotonin release in the prefrontal cortex and other areas of the brain synergistically when you give SSRIs and SNRIs. That's a really interesting finding, which means we're actually going after the root cause of depression, not trying to sleep, trying to treat sleep to get at depression, if you know what I mean. So I think, I think the same is true for ADHD. We were looking very carefully at acetylcholine release. We were looking at a lot of behavioral models in animals. And so these things make a lot of sense as you look at applying this, this, this methodology into other areas of neuroscience. And that's kind of our, our philosophy of what's going to give us the best return. But it also has a very strong probability of success. Understood.
Now, it's interesting, if you look at... Some of the FDA review documents, the Japanese review documents, Takeda actually was in pretty in-depth discussions with the agencies about getting a cognition benefit. For the orexin in type one. And it goes directly to your point where I think people think, all right, well, this is going to make you feel more awake. That's why, you know, you're going to have a benefit in certain subscales. But it does seem like there is a element of cognition improvement that's distinct from simply wakefulness improvement. I know your team has a view on this as well. What have you learned looking at some of the FDA's interactions with Decada, but then also some of the data you have in-house?
Well, I think we've seen across our programs that these mechanisms have cognitive benefit, and in fact, when we look at our existing programs, our narcolepsy type 1 study, our narcolepsy type 2 study, we included direct cognition measurements as part of those studies. We were able to show very clearly that you could take patients from moderate and severe levels of cognitive deficit to normal, and we see it consistently across the programs and in a dose-responsive way. So both us as well as Takeda have recognized this in our programs, and both of us have had interactions with the FDA about how do you approach this? Do you apply this? Does this show up in your clinical table? Do you actually get a separate claim for that? I think more clinical work would be needed there to demonstrate that, but we definitely feel that it's, this is not being pseudo-specific, that in fact you are getting a separate cognitive benefit outside of just sleep, and that also applies to fatigue as well. We did exactly the same thing with fatigue in our NT1 and NT2 studies. We put the PROMIS fatigue scale in each of those studies and saw similar outcomes to what we saw with cognition. Understood.
Now, I think one of the more under-discussed data sets, but probably quite important in this space, was the maintenance data that your team showed earlier this year in type 1 but also type 2 narcolepsy. And what kind of really stood out to me was, A, that patients chose to get on higher doses because they felt increasingly probably comfortable with the safety profile, but then, B, there was actually a deepening of response, not just on MWT, where I think there's been a lot of focus on, but on multiple different assessments. What did you learn from that maintenance data that you can apply to your development program outside of hypersomalance indications?
Well, I think your point is really well taken, that as you look at some of these new mechanisms, understanding the depth and duration of effect is really interesting. And, you know, you have to pick an arbitrarily end point when you run these studies. It could be four weeks, six weeks, eight weeks, whatever. But what we see is that with prolonged use, you're getting continued improvement. We also find, and you saw this in our NT2 study, that patients may have a preferred dosing lane. It may be you're randomized in the randomized trial to a dose that's not optimal for you, but when you optimize that dose for a patient, they get a continued benefit moving forward. So we see that in some of our programs as we think of ADHD, as we think of MDD, trying to understand how the effect size evolves over time is actually going to be an important element of our studies.
Good morning, everyone, and welcome to the call. You know, you have an idiopathic hypersomnia study reading out either end of year or next year. Sandy's looking at me, making it right. But it's interesting. I talked to a lot of investors. They're like, oh, I love the 2020 setup, 2027 setup for alchemies. I'm just nervous into this IH data. And I don't sense the same, let's say, nervousness from your team. Or that binary nature. And why is that the case, right? Like, why does your team, because I feel like your team is getting increasingly confident, we are going to be moving forward in IH. We just don't know exactly what that format's going to be.
Yeah, I mean, it's an interesting question. I think people, as you think about these indications, it's natural for people to want to segregate. Say you have an NT2 patient, NT1 patient, or an IH patient. What I think a lot of folks aren't realizing is that there's a lot of flow between these patient populations. The diagnosis between NT1 and NT2 is a little vague sometimes. Sometimes patients have cataplexy that's not recognized, but they're classified as an MT2, for example. On the other end, we see a lot of movement of patients between an IH diagnosis and a NT2 diagnosis. So as we think of the patient population that we're studying, we see it as being very similar to an NT2 population in the heterogeneity and how they respond to drug. They both have intact orexin tone, and so we would expect to see a similar effect size. As you're using, we're using the same dosing, once daily dosing, we're using the same doses. I think the main difference between the NT2 and the IH population is you do have a subgroup. You have a subgroup of long sleepers who are a little different phenotypically, but those long sleepers still experience excessive daytime sleepiness at rates similar to the NT2 group. And what we've seen with orexin agonism is that as you give super therapeutic levels of orexins, That you can drive wakefulness. You can drive them in normals. You can drive them in NT2 population. So we would expect to see the long sleepers perform well as well. I think where people see the risk, I guess, is that we're kind of pushing new boundaries here. This is the first time that anorexin agonist has been used in a broad IH population. And what we can't do right now is just quantify that effect size. That's the purpose of this study. How do you design your Phase 3 to have a statistical outcome that gets you a clinically meaningful outcome for patients?
But I will say... You guys have still said, look, when we think about the type of signal we're looking at, two to three points, specifically adjusted on ESS, seems like a reasonable bar. Is that still hold true?
Yeah, I mean, that's a clinically meaningful movement on the scale. The unmet need in IH is tremendous. There's really one branded drug there, which is Zywave right now. And oxibates are great drugs, but they're not for everybody. And I think an orexin agonist in the IH space is heavily needed. And remember, when we started our program, we started working in narcolepsy type 1, narcolepsy type 2. We had some hesitation about IH because of IRA concerns and other things. The patient community came to us. They were very clear. They were looking for medicines here. And so if you can show a clinically meaningful benefit in any way, they're more than happy to utilize your drug or to consider using your drug.
So now, I remember when the NT2 data came out and your team was having discussions, you talked about, you know, we're going to look at a BID formulation and maybe that we get a little, you know, better target coverage kind of in those last reads. I want you to kind of update, but one of the interesting things that I remember, you know, you and Richard were mentioning is, you know, we're seeing kind of two phenotypes. You know, one group that would benefit from maybe BID dosing because we're seeing it in the curves and then it drops off, and then maybe another, you know, group where even if we dose more, we wouldn't necessarily have a benefit. Do you still have that view that there's, like, maybe two distinct phenotypes now that you actually have maintenance data, right? And that's really where it gets interesting because – and can you talk a bit about that? Are there two different phenotypes in MWT, and then are there two different phenotypes in ESS? Do you still think that's the case here?
Well, yeah, I think as you look at the patient population here, within NT2, their sensitivity to erexin agonism can vary. And I don't know whether it's two distinct populations or it's a spectrum of response. And so when you look at our OLE data, for example, you see more of a spectrum of response. You see a group of patients at different dose levels who perform differently. I think the one thing, though, that we saw with the MWT test in our NT2 study is that that's a very sensitive test to specific time points in the course of a day. In a subset of patients, we saw that they were less responsive in the afternoon. We didn't see that in the total population. So that group would benefit best from a split dose, and it was actually the impetus of us putting split dosing across our programs.
Have you looked at split dosing in a maintenance setting yet?
This will be the first result that we'll see with split-dose performance in a clinical study, and I think that's part of why people are very interested in this data set.
Understood. Now, I guess maybe going into phase three, one of the things that, you know, your team's hinted at is, look, the dose range we explored here may not be actually the doses we take into phase three, and we feel increasingly comfortable about the safety profile. Um, of these orexins. So can you talk about, especially in your maintenance studies, what you're seeing in terms of, you know, AEs that are actually longer lasting versus those that are really just, you know, acute ones that you get as your body's tolerating the drugs, but then they wane away over time?
Yeah, it's a good question. I think what we've seen across our programs and other programs that other companies have run is there is an adaptation that happens as a patient goes under the drug first time, and you do get some things like insomnia, for example, as a patient adapts to the new drug. That's sort of your circadian rhythm adjusting to a new event. Sometimes you'll see that with headache. We saw in our NT1 trial some visual disturbances that were associated with that early. That early onset piece. Really, the only long-term type AEs that you typically see, it's really polychorea, which is a frequency of urination. And we tend to see it. It's mainly mild to moderate. It tends to be persistent in those patients who have it, but it doesn't tend to bother them. It doesn't lead to discontinuations. And we also see that in response forms on global impression and things like that from patients in studies. They love being on the therapy still. They like the benefits it's giving. It's not disruptive to their treatment.
Understood. And then maybe thinking about face reason tweaks you can make in learnings you had. You mentioned, you know, maybe there's a titration scheme. How does titration, let's say implemented within a phase three, help deal with the rate of overall AEs, and how fast would that titration actually be for some of your trials?
Yeah, so the only area where we think a titration like that could help is in your NT1 population. What we saw in particular in our NT1 trials is that if you took a patient, they all have zero orexantone, and if you were to take them and put them on the highest dose right away, you would tend to see more of those early tolerance issues, and so what we've done for our phase three actually is we step them first through an active dose for a couple weeks, and once they've been on the active dose for a couple weeks, if they've been randomized to the high, then they'll move to the high dose, and what that does is give them a little bit of a ramp so they can acclimatize to the new drug. We're just moving them and pushing them too fast.
Understood. And do you feel like that might actually lead to differentiated safety relative to some of the decayed assets that we've seen in NT1?
It may. It's really hard to compare the different drugs, where we are, and the dose curve, and how we're dosing once daily versus their split dose, et cetera. So I think our goal in this trial was to maximize efficacy and try to minimize our AE profiles as much as possible. Too soon to say whether it'll differentiate on that end.
Understood. Now, on ADHD, and it's interesting, again, there's, like, investor perception, and then you talked to strategics as well, and then we talked to you. You're not, you know, it wasn't placebo. It doesn't sound like there was a placebo separation. You seem to be relatively unbothered with that. And I think the biggest tell is that when we look at your phase two study, you had every potential. Enrich patients with baseline sleepiness, you know, enhance the trial powering. Your stat design, you've talked about, you know, efficacy in line with certain stimulants. You're powered, really, to deliver that in phase two. That's a very big, you know, internal versus external kind of contrast right now, and I'm sure you've felt that, too, with, you know, talking to people. What do you see when you have the data in-house that maybe we're missing externally right now?
Well, I think when people are looking at the data set in the Phase 1B and they start talking about placebo comparison, they're trying to make a trial that it wasn't. It never was. This was a safety trial where we're trying to look at patients within an inpatient setting over two weeks. So by the end of the trial, we actually only had eight placebo patients on the study. What we've seen and makes us confident in the mechanism is in that 1B study, we had a number of different things that we put in there, a number of different patient-reported outcomes, physician-reported outcomes. We put objective measures in, and what we saw across those is we saw a consistent response. We saw robust responses. It was consistent regardless of how it was measured. We saw at our high dose, we saw a CGIS change of two in a two-week period of time. That's a pretty profound change, regardless of how you look at that. So for setting the size, though, to look at are you Vyvanse-level efficacy, you need that big Phase II study. It has to be powered correctly. We have the dose ranging so we can look at dose response. The purpose of the two studies is very different. And in order to do the bigger study, you're literally looking at more of an outpatient setting. It's a four-week outpatient versus R1B, which is a two-week inpatient. Two very, very different characteristics.
Understood. Another trial you have coming up next year, I would argue probably flying under the radar, is your fatigue study, right? So an MS and Parkinson's study. Fatigue. And, you know, you guys have an underlying biological hypothesis, and then you're really curious what plays out in the clinic. So help us understand, why choose? MS and Parkinson's as kind of your two initial fatigue indications, and what are kind of two different clinical development pathways that branch out of that result?
Well, I'll start with the last question first, because when we looked at fatigue, fatigue is one of those areas that when you look at a lot of neuroscience as a whole and a lot of neurogenic disease, you see fatigue really plaguing a lot of these patients. And we were hearing clearly in some of these programs how disruptive it is to patients' lives. And so you can think of big indications, things like chronic fatigue and things like that. You can think of cancer treatment fatigue. We picked Parkinson's disease fatigue and MS fatigue to start because what we want to try to do is characterize this disease a little more thoroughly. And one of the things you tend to hear when people talk about fatigue, because they don't know what the etiology is, they tend to talk about central fatigue and peripheral fatigue. So central fatigue being this exhaustion that you feel mentally. MS patients tend to describe that as their primary fatigue. When you talk to Parkinson's patients, they tend to describe more of a peripheral fatigue, a muscular fatigue, this bone-tired muscles, and you almost could expect that. If you think of the diseases, it's what they're experiencing that's different. So they could be just describing the same disease in a different way. We want to know how orexin agonism works in these two different types. And then we also want to test their individual scales, so the Promise Fatigue Scale, the MS Fatigue Scale, the PD Fatigue Scales, to sort of see which is the most sensitive and accurate to assess these. And then we can meet with the FDA to talk about what's our path forward to develop these, and then to go into broader markets thereafter. So it's actually a data-rich study that's going to tell us a lot, and it will really point to what it's going to take to take it, not only in these indications, which are large, but into the bigger indications that are more broad.
Now, I can tell you, it did not surprise me to see a company like Lilly that has a vested interest in Alzheimer's look at, you know, an orexin agonist as maybe an asset they wanted in their pipeline. You guys have alluded to this, but I'd love to get your take as well, because I think there's a provocative argument that this could be an Aricept, right? It's something that actually, it's a cognitive enhancer. It's relatively tolerable. It could be used as an adjunct therapy. So, you know, companies that are trying to commercialize Alzheimer's. Do you see... Validity in that way, you know, pathway of thinking. You don't necessarily have trials there right now. But what would be the use of an orexin in an adjunct Alzheimer's setting?
No, it's a great question. I think if you look at a lot of the therapies for Alzheimer's right now, they're taking a very different approach to treatment. And I think when you take something like a memantine that's had a lot of benefit in use, but you could really improve on that with something that is driving a central mechanism. So, adjunctive therapy in Alzheimer's is definitely an interesting area, and we've identified a number of areas in neuroscience where you could use this. It comes with complications, as you can imagine. Elderly population, there's things going on with the brain and the ability to do that. So, you know, when we talk about probabilities of success and investment, some of the ones we've picked now are a little more proximal. But that's definitely somewhere you could take erection agonism.
Understood. Now... I think there's been, it's funny, I've never seen more people bring just a calculator. They're like, here's the prevalence, here's a number, and then here's your peak sales. And you'll see that sometimes when we talk about pancreatic cancer. But I'm sure you've heard a similar kind of way of thinking when you think about narcolepsy and pricing expectations. You know... Takeda came out, and they came at a premium to sodium oxabate. And every investor is like, well, Takeda, why did you do this? You could have priced more. Why do you think Takeda did choose to price their drug where they did? How does that allow them to actually get rapid access out of the gate? And then how does that change your pricing decisions when your drug gets into the market?
Well, look, I think as Takeda is coming out with their drug Rosafil, they're building a new market, a whole new mechanism that they're going to have to educate patients on, educate physicians on. They're working with the payers to work through that system. They also have a global business that they're putting in place, and they have a lot of considerations that they're looking at. And by any measure, that's a high-priced medication. And I think if you look at diseases of hypersomnolence and just kind of the treated populations, you're in the $25-ish billion range for an addressable market. So these are big markets. I think Takeda is balancing the best it can do with the business and how it wants to do and how it's assessed access. And we'll be watching carefully to see how that performs. Obviously, we have a lot of flexibility with our program. Three different indications, multiple doses, single dose, split dose, so there's a lot of flexibility in how we approach that in the future, and we'll see how things progress and go from there.
Understood. Last question before we let you go. I was surprised, and actually, our team went to Asia and spoke with Decadia, and I think they also were surprised to see an LDL increase with TAC861. And it showed up, I don't think they had published on that previously. Have you looked at impact of orexin? Do you think that's maybe an on-target effect or maybe something related to an individual scaffold?
I mean, I think it's something we haven't seen in our program, so I'm not sure it's necessarily an on-target effect. We do know, for example, that there's an interplay between sort of weight and lipids as patients go through their disease state. So when we wash people out of their existing drugs, for example, they'll eat excessively to stay awake. And so you'll see challenges there. So I don't know whether it's a function of disease shining through or whether it's something different. Thank you very much. We will look forward to that.
Wonderful conversation, I really did enjoy it. Thanks so much.
0:02 to 25:06 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Okay, cool. Good afternoon, everyone. Day three of our Jeffrey's Linden Healthcare Conference. Tail end of the day. We're going to make it through. My name is Akash Shawari. I am a farm and biotech analyst here at Jefferies, and I have the pleasure of hosting the Alchemist management team and Blair. Alchemist is one of…
Blair: Great. Well, thanks for having me here. It's great to see you again. You know, we're coming off a pretty transformational time for the company. This last year, we had a number of data readouts that have kind of moved us into the new space. We had the NT2 data…